Astellas Pharma (OTC: ALPMY)
Astellas Pharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Astellas Pharma Company Info
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
News & Analysis
Why It's So Dang Hard to Value Biotech Deals
There's more to the deals than the big headline numbers.
What Pfizer Gets in Its $14 Billion Medivation Deal
Pfizer is paying $81.50 per share in cash to acquire Medivation's oncology drugs.
What Sent Medivation, Inc.'s Shares Soaring 25.1% In April
Rumors that a suitor might step up to acquire this mid cap cancer company sparked investor enthusiasm.
Sanofi's Bid for Medivation Is Too Low
A top-selling cancer drug already on the market and more in the wings make this biotech a very attractive M&A target.
J&J's Q1 Results Suggest More Upside for Medivation, Inc.
Weak growth for Zytiga may be due to stronger growth for Xtandi.
How Biotech Is Getting Berned by Sanders
Bernie Sanders and other members of Congress have Medivation's Xtandi in the cross-hairs, but a decision on Xtandi could have wide-ranging implications for the industry and investors.
Why Medivation Shares Are Tanking Today
Congressmen have put Xtandi's price in their cross-hairs.
Medivation Inc. Stock Is Rising Today -- Here's Why
An earnings beat, mixed with upbeat guidance, puts the company's investors in a good mood.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.